Concurrent Fludarabine and Total Body Irradiation (F-TBI) for Patients with Advanced Relapsed, Refractory, or Resistant Indolent Non-Hodgkin's Lymphoma (NHL): A Phase I Trial.

Reviewer: William Levin, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 10 de diciembre del 2001

Share article


Presenter: David Eilender
Presenter's Affiliation: Wayne State University
Type of Session: Poster

Background

  • Both chemotherapy (CHT) and radiation therapy (RT) are used in the treatment of non-Hodgkin's lymphoma (NHL).
  • It is well known that when certain chemotherapeutic agents are given with RT there is a synergistic effect.
  • The current study investigates the combination of Fludarabine and total body irradiation (TBI) in the treatment of patients with advanced relapsed, refractory, or resistant indolent NHL.
  • The goal of this Phase I study was to determine the toxicity and maximum tolerated dose (MTD) of F and TBI (F-TBI).
  • The other aim of the study was to observe the response of F-TBI in patients with relapsed, refractory NHL.

    Materials and Methods

      Elgibility:
    • Advanced relapsed, refractory, or resistant indolent NHL.
    • Previously treated, but not post-bone marrow or peripheral stem cell transplant.
    • Good renal function,absolute neutrophil count and platelet count.
    • Good perfomance status
    • Criteria for dose-limiting toxicity (DLT) (any of the following 4:
      1. Plts <20x10(9)(ten-to-the-9th) or an ANC <0.5x10(9) for >10 days.
      2. Plts not >100x10(9) or ANC not >1.5x10(9) by day 43.
      3. If bone marrow >30%, then plts not >50x10(9) or ANC >0.8x10(9) for the first 2 cycles, by day 43.
    • Maximum tolerated Dose (MTD)
      1. Maximum dose level RT, with DLT in <3 of 8 patients.
      2. Treat at least 8 patients at the MTD.

    Results

  • 20 pts were enrolled from 1998-2001
  • 6 pts were enrolled at the first dose level (F was 25mg/m2/d IV and TBI was 0.1Gy/d given on d1-3 q4-6 wks)
  • 5 pts were enrolled at the second dose level (TBI dose was 0.15 Gy/d), 3 of them did not receive >3 cycles due to prolonged thrombocytopenia.
  • Since the intent of the study was to give 4-6 cycles of F q4-6 weeks 9 more patients were enrolled at the first TBI dose, the MTD.
  • DLT was prolonged thrombocytopenia.
  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

    Más información